Note: This is not an exhaustive list. Deals were reported by Becker’s Hospital Review and are presented in the order in which they were reported.
- Astellas Pharma to acquire Audentes Therapeutics in $3B deal
Astellas Pharma, a Tokyo, Japan-based drugmaker, plans to acquire San Francisco-based Audentes Therapeutics for about $3 billion. - Novartis pays $9.7B to acquire Medicines Co.
Novartis has acquired Parsipanny, N.J.-based drugmaker Medicines Co. for $9.7 billion. - Alkermes to acquire Rodin Therapeutics
Alkermes will acquire Boston-based drugmaker Rodin Therapeutics for $100 million to expand its portfolio of drugs to treat neurodegenerative disorders. - FTC clears Bristol-Myers takeover of Celgene
The Federal Trade Commission cleared the way for Bristol-Myers Squibb to complete its acquisition of Celgene for $74 billion, one of the largest deals in pharmaceutical history. - Roche to buy small Massachusetts drugmaker for $390M
Roche will pay $390 million to purchase a small Lexington, Mass.-based drugmaker, Promedior. - Amgen invests $2.7B in Chinese drugmaker
Amgen is investing $2.7 billion in a Chinese drugmaker, BeiGene, giving it a 20.5 percent stake in the company.
More articles on pharmacy:
Top 5 pharmacy stories in November
Juno Therapeutics co-founder starting new drug company
Parents in Europe crowdsource $2.7M to buy world’s most expensive drug for their toddler
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.